Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Paul G RichardsonSusanna J JacobusEdie A WellerHani HassounSagar LonialNoopur S RajeEva MedvedovaPhilip L McCarthyEdward N LibbyPeter M VoorheesRobert Z OrlowskiLarry D AndersonJeffrey A ZonderCarter P MilnerCristina GasparettoMounzer E AghaAbdullah M KhanDavid D HurdKrisstina GowinRammurti T KambleSundar JagannathNitya NathwaniMelissa AlsinaR Frank CornellHamza HashmiErica L CampagnaroAstrid C AndreescuTeresa GentileMichaela LiedtkeKelly N GodbyAdam D CohenThomas H OpenshawMarcelo C PasquiniSergio A GiraltJonathan L KaufmanAndrew J YeeEmma ScottPallawi TorkaAmy FoleyMariateresa FulcinitiKyle HebertMehmet K SamurKelly MasoneMichelle E MaglioAndrea A ZeytoonjianOmar NadeemRobert L SchlossmanJacob P LaubachClaudia Paba-PradaIrene M GhobrialAurore PerrotPhilippe MoreauHervé Avet-LoiseauMichel AttalKenneth C AndersonNikhil C Munshinull nullPublished in: The New England journal of medicine (2022)
Among adults with multiple myeloma, RVD plus ASCT was associated with longer progression-free survival than RVD alone. No overall survival benefit was observed. (Funded by the National Heart, Lung, and Blood Institute and others; DETERMINATION ClinicalTrials.gov number, NCT01208662.).